Se prevé que el mercado de Diltiazem alcance los 832,52 millones de dólares en 2028, frente a los 369,95 millones de dólares de 2021; se espera que crezca a una tasa compuesta anual del 12,3% de 2021 a 2028.
Factores como el aumento de la incidencia de enfermedades cardiovasculares y el aumento de la población de edad avanzada están impulsando el crecimiento del mercado. Sin embargo, es probable que los efectos secundarios del diltiazem obstaculicen el crecimiento del mercado.
Las enfermedades cardíacas se observan principalmente en personas mayores debido a su débil inmunidad y otros problemas de salud importantes. Los factores generales del envejecimiento provocan un endurecimiento del corazón y de los vasos sanguíneos, lo que provoca trastornos cardíacos. A medida que avanza la edad, la presión arterial sistólica también aumenta y puede provocar enfermedades cardiovasculares. Por tanto, la presión arterial alta es una causa común de enfermedades cardíacas en personas de 75 años o más. La enfermedad de las arterias coronarias y la insuficiencia cardíaca son las siguientes afecciones causadas. Aunque la incidencia de arritmias abarca a personas de todos los grupos de edad, su incidencia está aumentando significativamente entre las personas mayores.
Según la encuesta Global Ageing 2019, la población mundial de personas de 65 años o más ascendía a 703 millones en 2019. Se espera que el grupo demográfico de personas mayores se duplique a 1.500 millones de personas para 2050. Es probable que la frecuencia de una persona de 65 años o más aumente de 1 de cada 11 habitantes en 2019 a 1 de cada seis habitantes en 2025. Este grupo demográfico es más susceptibles a enfermedades cardiovasculares, como arritmias. Del mismo modo, según la OMS, se estima que el porcentaje de personas de 60 años o más alcanzará el 22% en 2050, frente al 12% en 2015. Según el informe "Older Americans 2016: Key Indicators of Well-Being" de la Federal Interagency Foro sobre estadísticas relacionadas con el envejecimiento, el 35,8% de las personas de 85 años o más tenían un trastorno cognitivo leve o extremo. Además, según el informe sobre el envejecimiento de la población mundial 2017 de las Naciones Unidas, en 2017 había 962 millones de personas en todo el mundo que tenían 60 años o más, y se espera que esa cifra alcance casi 2.100 millones en 2050.
< p>Según la Oficina del Censo de EE. UU., se espera que el número de estadounidenses de 65 años o más se duplique con creces, de 46 millones en 2016 a más de 98 millones en 2060, y el grupo de edad de 65 años o más representará aproximadamente el 24%. de la población mundial, frente al 15% en 2016. En 2017, la Unión Europea tenía la mayor proporción de personas de 60 años o más (25%). Otras regiones del mundo también están experimentando un envejecimiento de la población cada vez mayor, y para 2050, todas las regiones del mundo, excepto África, tendrán aproximadamente una cuarta parte o más de sus habitantes de 60 años o más. Se prevé que el número de personas mayores en el mundo alcanzará los 1.400 millones de dólares en 2030 y los 2.100 millones de dólares en 2050 y superará los 3.100 millones de dólares en 2100. La población de edad avanzada es más propensa a presentar presentaciones atípicas, condiciones comórbidas, y resultados desfavorables. Los cambios estructurales y funcionales en el sistema cardiovascular asociados con el envejecimiento son causas importantes de enfermedades cardiovasculares. Por lo tanto, el aumento de la población geriátrica en el mundo conduce a un aumento en la incidencia de enfermedades cardiovasculares, lo que impulsa el crecimiento del mercado de diltiazem.regiones lucrativas para el mercado de diltiazem
Perspectivas del mercado
Aumento de la incidencia de enfermedades cardiovasculares
El diltiazem es un bloqueador de los canales de calcio. Reduce la frecuencia cardíaca y actúa relajando los vasos sanguíneos del cuerpo y el corazón. La sangre fluye más fácilmente y el corazón trabaja menos para bombear sangre. El diltiazem disminuye la demanda de oxígeno del miocardio mediante una reducción de la frecuencia cardíaca, la presión arterial y la contractilidad cardíaca, representando también una buena alternativa para el tratamiento de la angina crónica estable. El diltiazem tiene potentes efectos cardiovasculares causados por sus acciones sobre el músculo liso vascular, el miocardio ventricular y el tejido conductor especializado. En individuos con función ventricular normal, induce vasodilatación coronaria y periférica, tiene un impacto cronotrópico y dromotrópico negativo y tiene poco o ningún efecto inotrópico negativo. Diltiazem tiene uso potencial en una amplia variedad de trastornos cardiovasculares. Es extremadamente eficaz para aliviar el espasmo de la arteria coronaria asociado con la angina variante. En comparación con los nitratos en pacientes con angina de esfuerzo, el diltiazem tiene una eficacia similar.
Según la Organización Mundial de la Salud, las enfermedades cardiovasculares (ECV) son la principal causa de muerte en todo el mundo. Las ECV son una causa importante de morbilidad y afectan a más personas que cualquier otra enfermedad. Algunas enfermedades cardiovasculares son la enfermedad cerebrovascular, la enfermedad coronaria y la enfermedad cardíaca reumática. El consumo de tabaco, una dieta poco saludable y la inactividad física se encuentran entre los principales factores del estilo de vida que aumentan el riesgo de ataques cardíacos y accidentes cerebrovasculares. Además, otros factores de riesgo que pueden provocar enfermedades cardiovasculares son la presión arterial alta, la diabetes y el aumento de los niveles de colesterol.
La fibrilación auricular (AFib) es el tipo más común de trastorno cardíaco, en el que el corazón late demasiado rápido. , demasiado lento o de forma irregular. Los Centros para el Control y la Prevención de Enfermedades (CDC) estimaron que entre 2,7 millones y 6,1 millones de personas padecen AFib en Estados Unidos. En 2017, alrededor de 166.793 certificados de defunción mencionan la AFib y fue la principal causa de muerte en 26.077 muertes. Cada año se informan más de 454 000 hospitalizaciones y alrededor de 158 000 muertes debido a AFib en los EE. UU.
Además, la Sociedad Europea de Cardiología informó que la fibrilación auricular es la arritmia más común y representa del 0,28 % al 2,6 % de la atención sanitaria. gasto en los países europeos. También mencionó que los pacientes que padecen fibrilación auricular tienen un riesgo cinco veces mayor de sufrir un derrame cerebral. Del 20% al 30% del total de accidentes cerebrovasculares en Europa se deben a la fibrilación auricular. Según el estudio realizado por la Sociedad Europea de Cardiología en 2016, ~7,6 millones de personas de 65 años o más en la UE padecían fibrilación auricular. La Sociedad Europea de Cardiología estimó que se espera que el número aumente en un 89% para 2060 y ~14,4 millones de personas tendrán fibrilación auricular. Además, se espera que la prevalencia del 7,8 % alcance el 9,5 % en 2060.
Además, la prevalencia de la fibrilación auricular en Asia Pacífico también está aumentando. Según el informe "MÁS ALLÁ DE LA CARGA: EL IMPACTO DE LA FIBRILACIÓN AURICULAR EN ASIA PACÍFICO" Según Biosense Webster, publicado en 2019, más de 16 millones de personas en Asia Pacífico sufren fibrilación auricular, que afecta a la población de mediana edad y a los ancianos. El informe también estima que la cifra alcanzará unos 72 millones en 2050.
Prevalencia de fibrilación auricular en APAC (por país)
Fuente: Informe Biosense Webster : MÁS ALLÁ DE LA CARGA: EL IMPACTO DE LA FIBRILACIÓN AURICULAR EN ASIA PACÍFICO
Los bloqueadores de los canales de calcio diltiazem (Cardizem) y verapamilo (Calan e Isoptin) son eficaces para el control inicial de la frecuencia ventricular en pacientes con fibrilación auricular. Estos agentes se administran por vía intravenosa en dosis en bolo hasta que la frecuencia ventricular se vuelve más lenta. Además, el diltiazem reduce la conducción en el nodo auriculoventricular, lo que también es útil para el control de la frecuencia cardíaca en pacientes con fibrilación auricular. Por lo tanto, la creciente prevalencia de la fibrilación auricular en todo el mundo impulsa el crecimiento del mercado de diltiazem.
Información basada en el tipo de producto
Según el tipo de producto, el mercado se segmenta en cápsulas, inyecciones y tabletas. En 2021, el segmento de tabletas tuvo la mayor participación de mercado, mientras que se espera que el segmento de cápsulas experimente la CAGR más rápida entre 2021 y 2028.
Información basada en aplicaciones
Según la aplicación, el mercado se segmenta en angina, hipertensión y otros. En 2021, el segmento de hipertensión tuvo la mayor participación del mercado, mientras que se espera que el segmento de angina crezca al ritmo CAGR más rápido durante los próximos años.
Perspectivas estratégicas
Las empresas que operan en el mercado de diltiazem enfatizan en adoptar la estrategia de innovación de productos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca en el mercado global.
Diltiazem Market – Segmentación
Por tipo de producto
- Tableta
- Cápsulas
- Inyección
Por aplicación
- Hipertensión
- Angina
- Otros
Mercado de Diltiazem– por Geografía
- América del Norte
- Estados Unidos
- Canadá
- México
< li>Europa - Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Oriente Medio y África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- América del Sur y Central (SCAM )
- Brasil
- Argentina
- Resto de ESTAFA
Perfiles de Empresas
- Bausch Health
- Teva Pharmaceutical Industries Ltd
- Mylan NV
- Athenex
- Pfizer, Inc,
- Glenmark
- Sandoz (Novartis Ag)
- Sun Pharmaceutical Company Ltd
- Hikma Pharmaceuticals
- Zydus Pharmaceuticals >ul>
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. 12 At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.
The factors that are driving and restraining factors that will affect Diltiazem market in the coming years. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
The Diltiazem market majorly consists of the players such as Bausch Health, Teva Pharmaceutical Industries Ltd, Mylan N.V, Athenex, Pfizer, Inc, Glenmark, Sandoz (Novartis Ag),Sun Pharmaceutical Company Ltd, Hikma Pharmaceuticals, Zydus Pharmaceuticals among others amongst others.
The US is the largest market for Diltiazem at a global level., In the United States hypertension was a primary or contributing factor in roughly half a million deaths in in recent years. Hypertension-related deaths have increased by 72 percent and 20 percent in rural and urban areas of the United States, respectively. According to Centers for Disease Control and Prevention, high blood pressure costs the United States about $131 billion each year. In the United States, heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. According to the WHO in the United States, one person dies from cardiovascular disease every 36 seconds. Every year, over 655,000 Americans die from heart disease, accounting for one out of every four deaths.
The global diltiazem market based on product is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market, by product type. However , the capsules segment of Diltiazem Market is also expected to witness fastest CAGR of 12.8% during 2021 to 2028. Factors such as increase in cardiovascular disease incidence and increasing elderly population are driving the market growth. However, side effects of diltiazem is likely to hamper the growth of the market.
Asia Pacific is expected to be the fastest-growing region and is likely to expand at a high growth rate due to government initiatives in drug approval process. Moreover, the rise in prevalence of cardiovascular disease such as angina, hypertension and arrythmia is likely to boost the growth of market in Asia-Pacific region. For instance, The rise in the cardiovascular diseases is observed due to the rise in the risk factors such as smoking, blood pressure, cholesterol and diabetes. The percentage of men who smoke in Japan is approximately 35.4% which is nearly double than the rate of smoking in US. The average blood pressure in Japan is nearly 130.5 and the cholesterol leverage averages approximately 201 mg/dl (5.2 mmol/L). However, the rate of diabetes is little less, compared to the rate in US. The rate of diabetes in Japan is approximately 7.2%. Owing to these factors the country is likely to demand more of the cardiovascular diagnostic and treatment devices in future.
The List of Companies - Diltiazem Market
- Bausch Health
- Teva Pharmaceutical Industries Ltd
- Mylan N.V
- Athenex
- Pfizer, Inc
- Glenmark
- Sandoz (Novartis Ag)
- Sun Pharmaceutical Company Ltd
- Hikma Pharmaceuticals
- Zydus Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Aug 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Aug 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Aug 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)